Dr. Martens (LON:DOCS) Reaches New 12-Month High - Here's Why

Key Points

• Dr. Martens plc reached a new 52-week high of GBX 92.55 ($1.25) during trading, reflecting increased investor interest.
• Analysts have mixed views on the stock, with Royal Bank of Canada reducing its price target to GBX 6,000, while Peel Hunt upgraded it to a "buy" rating.
• The company reported earnings per share of GBX 2.40 for the last quarter and has a market cap of £893.10 million.

Dr. Martens plc (LON:DOCS - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as GBX 92.55 ($1.25) and last traded at GBX 92 ($1.24), with a volume of 328376 shares changing hands. The stock had previously closed at GBX 91.15 ($1.23).

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on DOCS. Peel Hunt raised Dr. Martens to a "buy" rating in a report on Monday, August 18th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Dr. Martens in a report on Friday, July 11th. Finally, Royal Bank Of Canada decreased their price target on Dr. Martens from GBX 7,000 to GBX 6,000 and set a "sector perform" rating for the company in a report on Monday, May 19th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Dr. Martens has an average rating of "Hold" and an average target price of GBX 6,000.

Dr. Martens Price Performance

The firm has a market capitalization of £875.30 million, a PE ratio of 18,130.00, a PEG ratio of 6.40 and a beta of 0.11. The stock has a 50-day moving average price of GBX 80.04 and a 200 day moving average price of GBX 66.43. The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27.

Dr. Martens (LON:DOCS - Get Free Report) last posted its quarterly earnings data on Thursday, June 5th. The company reported GBX 2.40 EPS for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. Equities analysts forecast that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.